# The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

> **NCT04800692** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Louis Messina** · enrollment: 10 (estimated)

## Conditions studied

- Claudication, Intermittent
- Peripheral Artery Disease
- Peripheral Vascular Diseases

## Interventions

- **DRUG:** Tetrahydrobiopterin 10 mg/kg
- **DRUG:** Tetrahydrobiopterin 20 mg/kg
- **DRUG:** L-Ascorbate
- **DRUG:** L-Arginine

## Key facts

- **NCT ID:** NCT04800692
- **Lead sponsor:** Louis Messina
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-15
- **Primary completion:** 2027-07
- **Final completion:** 2027-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04800692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04800692, "The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04800692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*